<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01856998</url>
  </required_header>
  <id_info>
    <org_study_id>PROP-001-CP3</org_study_id>
    <secondary_id>2012-005701-43</secondary_id>
    <nct_id>NCT01856998</nct_id>
  </id_info>
  <brief_title>Therapeutic Equivalence (TE) Study of Propofol 2% MCT Fresenius (MCT=Medium-Chain Triglycerides) Compared With Diprivan® in Patients Undergoing Elective Surgery</brief_title>
  <acronym>PropofolTE</acronym>
  <official_title>Therapeutic Equivalence Study of Propofol Using Target-Controlled Infusion of Propofol 2% (20 mg/mL) MCT Fresenius Compared With Diprivan® 20 mg/mL (AstraZeneca) in Patients Undergoing Elective Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Kabi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fresenius Kabi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the therapeutic equivalence, based on&#xD;
      pharmacodynamic parameters of Propofol 2% (20 mg/mL) MCT Fresenius and Diprivan® 20 mg/mL&#xD;
      (AstraZeneca), administered by target controlled infusion (TCI).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Loss of Eyelash Reflex (LOER)</measure>
    <time_frame>Every ten seconds from the initiation of TCI anesthesia device until LOER occurs up to 150 seconds. If LOER has not occurred within this timeframe, target propofol concentration to be increased by 1 μg/mL every 60 seconds until LOER is observed.</time_frame>
    <description>The overall timeframe until LOER is observed depends on the patient and varies from only a few seconds up to 240 seconds in total.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>General Anesthesia</condition>
  <condition>Elective Surgery</condition>
  <arm_group>
    <arm_group_label>Diprivan® 20 mg/mL (AstraZeneca)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dosage form: lipid emulsion&#xD;
Dosage: Initial effect-site target concentration: 5 μg/mL, if necessary increased by 1 μg/mL every 60 seconds until LOER&#xD;
Frequency: continuously (will be adjusted to keep Bispectral Index (BIS) between 40 and 60, however maintenance target concentration can be increased if a patient needs a BIS &lt;40 with regard to individual condition and the respective surgery)&#xD;
Duration: Until end of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol 2% (20 mg/mL) MCT Fresenius</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage form: lipid emulsion&#xD;
Dosage: Initial effect-site target concentration: 5 μg/mL, if necessary increased by 1 μg/mL every 60 seconds until LOER&#xD;
Frequency: continuously (will be adjusted to keep Bispectral Index (BIS) between 40 and 60, however maintenance target concentration can be increased if a patient needs a BIS &lt;40 with regard to individual condition and the respective surgery)&#xD;
Duration: Until end of surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <arm_group_label>Propofol 2% (20 mg/mL) MCT Fresenius</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diprivan</intervention_name>
    <arm_group_label>Diprivan® 20 mg/mL (AstraZeneca)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects ≥18 years and &lt;65 years old&#xD;
&#xD;
          2. Able to understand and give signed and dated written informed consent&#xD;
&#xD;
          3. Body mass index (BMI) ≥20 and ≤30 kg/m² at screening&#xD;
&#xD;
          4. ASA (American Society of Anesthesiologists) physical status 1 or 2&#xD;
&#xD;
          5. Undergoing elective, minor orthopedic, vascular, urological, or gynecological surgery&#xD;
&#xD;
          6. Patients should be affiliated to a social security scheme and benefit from the&#xD;
             corresponding rights and cover&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The following planned procedures are to be excluded:&#xD;
&#xD;
               -  Day surgery&#xD;
&#xD;
               -  Emergency surgery&#xD;
&#xD;
               -  Total hip or total knee replacement&#xD;
&#xD;
               -  Requiring opening of the great cavities of the body (cranium, thorax, peritoneum,&#xD;
                  or pelvis)&#xD;
&#xD;
               -  With routine risk, even if low, of hemorrhage severe enough to require&#xD;
                  administration of colloid or blood products&#xD;
&#xD;
               -  With routine risk, even if low, of death during or soon after the procedure&#xD;
&#xD;
               -  Vascular surgery involving the aorta, venae cavae, iliac arteries, or femoral&#xD;
                  arteries&#xD;
&#xD;
          2. Intended administration of IV medications through a central venous catheter (Note: a&#xD;
             central venous catheter may be used to obtain Pharmacokinetic (PK) samples, though&#xD;
             only if no port of the catheter is being used for administration of any other product,&#xD;
             including crystalloid infusion at more than a &quot;keep line open&quot; rate)&#xD;
&#xD;
          3. Administration of general anesthesia or propofol within the 7 days prior to&#xD;
             randomization&#xD;
&#xD;
          4. History of hypersensitivity to propofol, eggs, soya, peanuts, or any other constituent&#xD;
             of the study drugs&#xD;
&#xD;
          5. ASA physical status ≥3&#xD;
&#xD;
          6. History of major anesthesia complications including, but not limited to:&#xD;
&#xD;
               -  Clinically significant hypoxia&#xD;
&#xD;
               -  Profound hypotension&#xD;
&#xD;
               -  Anaphylaxis or anaphylactic reactions&#xD;
&#xD;
               -  Unpredictable anesthesia agent requirements&#xD;
&#xD;
          7. History of difficult airway management including, but not limited to:&#xD;
&#xD;
               -  Problematic artificial ventilation with face mask&#xD;
&#xD;
               -  Repeated difficulty of placement of laryngeal mask airway (LMA)&#xD;
&#xD;
               -  Difficult laryngeal intubation (Cormack-Lehane grade 3 to 4) and requiring&#xD;
                  alternative technique e.g. fibre-optic or awake laryngeal intubation&#xD;
&#xD;
          8. History of difficult venous access&#xD;
&#xD;
          9. Myocardial infarction within 6 months of randomization or a cardiac reperfusion&#xD;
             procedure within 6 weeks of randomization&#xD;
&#xD;
         10. Significant respiratory, cardiovascular, liver or renal disease as assessed by&#xD;
             investigator&#xD;
&#xD;
         11. Active systemic infection (localized infection related to surgical procedure is&#xD;
             allowable as long as there is no indication of systemic involvement)&#xD;
&#xD;
         12. History of psychiatric disorder, including use of sedatives or antidepressants for any&#xD;
             reason, within 6 months prior to randomization&#xD;
&#xD;
         13. Alcohol or other substance abuse within 2 years prior to randomization, as well as for&#xD;
             the duration of the study&#xD;
&#xD;
         14. Use of medication that could reduce the subject's respiratory and/or cardiac output&#xD;
&#xD;
         15. Female subjects who are pregnant, breastfeeding, or lactating&#xD;
&#xD;
         16. Hemoglobin &lt;7.5 g/dL at screening or randomization&#xD;
&#xD;
         17. Platelets &lt;50,000 x 10³/μL at screening or randomization&#xD;
&#xD;
         18. ECG findings detected at screening not consistent with the subject's medical history&#xD;
             or warranting cardiology review&#xD;
&#xD;
         19. Participation in an interventional clinical study within 6 months of screening&#xD;
&#xD;
         20. History of Propofol infusion syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francois Sztark, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Bordeaux, Groupe Hospitalier Pellegrin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Bordeaux, Groupe Hospitalier Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>May 8, 2013</study_first_submitted>
  <study_first_submitted_qc>May 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2013</study_first_posted>
  <last_update_submitted>February 20, 2014</last_update_submitted>
  <last_update_submitted_qc>February 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Therapeutic Equivalence</keyword>
  <keyword>Propofol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

